THU-044 CCN5 promotes fibrogenic activation of hepatic stellate cells and serves as a biomarker for liver fibrosis
Yunhao Duan(Tongji University), Yuzhen Zhang, Carolin V. Schneider(Translational Therapeutics (United States)), Gang Zhao(Xijing Hospital), Shougang Zhuang(Shanghai East Hospital), Hongda Li, Wenrun Wu(Shanghai East Hospital), Fan Ding(Huazhong Agricultural University), Fangying Ji, Jinnan Yue(Shanghai East Hospital), Frank Tacke(Medizinische Hochschule Hannover), Jinjiang Pi, Lin Zhang(Qingdao University), Qi Zhang(Peking University), Xiaoli Chen(BGI Group (China)), Yuting Zhang(Guilin Medical University), Jie Liu(Qingdao University), Christian Trautwein(Medizinische Hochschule Hannover), Bin Zhou(Tsinghua University), Kai Markus Schneider(RWTH Aachen University)
Cited by 0
Related Papers
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.4k
Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis
|Hepatology|2010|786